Biosimilar vs. Generic
| Characteristic | Generic Drug | Biosimilar |
|---|---|---|
| Molecule type | Small molecule (simple chemical) | Large molecule (complex biologic) |
| Manufacturing | Chemical synthesis | Living cell culture |
| FDA approval | Bioequivalence to reference drug | Highly similar to reference biologic |
| Cost savings | 80–90% vs. brand | 30–50% vs. reference biologic |
| Interchangeability | Automatically substitutable | Interchangeable designation required for automatic substitution |
Available Biosimilars
Dozens of biosimilars are now available in the US, including biosimilars for Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Rituxan (rituximab), Herceptin (trastuzumab), and Avastin (bevacizumab). The Humira biosimilars — launched in 2023 — represent the largest biosimilar opportunity in history, with potential savings of $5–$10 billion annually.
The Humira Opportunity
IQ Insight
Humira (adalimumab) is the world's best-selling drug — generating $20+ billion in annual US sales. Multiple biosimilars are now available at 30–50% lower cost. For an employer with 10 Humira patients at $6,000/month each, switching to a biosimilar at $3,000/month saves $360,000 annually. Humira biosimilar adoption is the single largest near-term pharmacy savings opportunity for most employer plans.